Medicines & Healthcare products Regulatory Agency

MHRA Central Freedom of Information Team
10 South Colonnade
Canary Wharf
London
E14 4PU

foi.request@mhra.gov.uk.

MHRA Website

[redacted]

Our Ref: **FOI2025/00948**

11 September 2025

Dear [redacted]

Thank you for your Freedom of Information (FoI) request received on 3 September. You wrote:

> *I just wanted to note that I have recently seen 2 patients on mounjaro reporting gout. Checking the BNF gout is not listed as adverse effect of using Mounjaro but wondered if it has been reported by anyone else*

MHRA Response

We can confirm that the Agency holds this information. However, the information is exempt under Section 21(1) of the Freedom of Information Act because the information is reasonably accessible to you, as it is already in the public domain.

The MHRA publishes reported side effects of a drug in the form of interactive Drug Analysis Profiles (iDAPs) which can be accessed using this website: https://yellowcard.mhra.gov.uk/idaps.

Here you will be able to access a complete listing of all UK suspected adverse drug reaction reports that have been reported to the MHRA via the Yellow Card scheme for tirzepatide.

Once you have navigated to the iDAP for tirzepatide (either using the search bar function or the Browse A-Z function), you can then navigate to the “Total Reaction Profile”. Here, a table breaking down reactions by System Organ Class (SOC) is available. You can then expand each category of reactions to see the number of reports for individual reactions.

For example, to identify the number of reports for the term “Gout”, you can expand the following terms in the Reactions by System Organ Class table:

“Metabolism and nutrition disorders”> “Purine and pyrimidine metabolism disorders”> “Disorders of purine metabolism”> “Gout”.

Please be aware that when reviewing the data within an iDAP it is important to do so in the context of the essential guidance at the bottom of the report to ensure that you do not misinterpret the data.

Please also be aware that iDAP data do not necessarily refer to proven side effects, and you should refer to the product information (Summary of Product Characteristics and Patient Information Leaflet) which can be found here: https://products.mhra.gov.uk/ for details on the possible side effects of a medicine.

Please be aware that "gout" is not listed in the Summary of Product Characteristics or Patient Information leaflet for the product "Mounjaro".

Please be assured that as with all medicines, the MHRA continuously monitors the safety of tirzepatide. Should any important safety issues be identified, appropriate regulatory action would be taken and communicated to healthcare professionals and patients alike.

If you have any queries about this letter, please contact us quoting the reference number above.

Yours sincerely,

MHRA Central Freedom of Information Team
Medicines & Healthcare products Regulatory Agency

Your right to complain under the Freedom of Information Act

If you are not happy with this response you may request an internal review by e-mailing foi.request@mhra.gov.uk or by writing to: MHRA Central Freedom of Information Team, 10 South, Colonnade, Canary Wharf, London, E14 4PU

Any request for an internal review must be received by us within 40 working days of the date of this letter. Please note we are not obliged to provide a review if it is requested after more than 40 working days.

If you are not content with the outcome of the internal review, you may apply directly to the Information Commissioner's Office for a decision. Generally, the Commissioner cannot make a decision unless you have exhausted our own complaints procedure. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.
Website: ICO FOI and EIR complaints or telephone 0303 123 1113

Re-use of our information
The MHRA information supplied in response to your request is subject to Crown copyright. Information created by the MHRA which is disclosed under the Freedom of Information Act is made available for re-use under the Open Government Licence (OGL) v3.0, except where this is otherwise stated. There are some restrictions on re-use under the OGL and these can be viewed here:
https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/